Compare Fabrinet (FN) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Twist Bioscience Corp — how do they compare? Fabrinet trades at $489.21 (market cap $17.46B), while Twist Bioscience Corp trades at $161.72 (market cap $10.08B). The key difference: Fabrinet is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 30 Days and Twist Bioscience Corp for 27 Days on average.
| FN | TWST | |
|---|---|---|
Market Cap | $17.46B | $10.08B |
Volume | 1,199,886 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $746.47 | $205.00 |
52-Week Low | $361.94 | $25.45 |
Typical Hold Time | 30 Days | 27 Days |
Enterprise Value | $16.59B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $493.25, down 0.95% amid mixed technical signals with bullish moving averages but overbought RSI readings. The company demonstrates strong fundamental performance with 45% Q4 revenue growth and consistent earnings beats, driven by surging AI data center demand. Analyst consensus remains strongly bullish with a $769.50 price target representing 56% upside potential, though the stock faces near-term pressure from high capital expenditures.
Fabrinet's AI infrastructure positioning and capacity expansion support long-term growth prospects, but investors should monitor customer concentration risks and margin pressures. The stock's premium valuation (P/E 37.34) requires continued execution on growth targets to justify current levels amid competitive optical component market dynamics.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
